Coramed Technologies Awarded NIH Small Business Innovation Grant

Nearly $3 Million over Three Years Will Help Make Next-Generation Hemostasis Monitoring a Reality

May 23, 2011—Niles, Illinois—The National Heart, Lung, and Blood Institute has awarded Coramed Technology $2.9 million over three years for the development of next-generation thrombelastograph technology for monitoring patient hemostasis on demand.

Known as coagulation resonance analysis or CORA, this project will take the technology from the prototype stage through FDA-cleared and CLIA-waived commercial products. The CORA devices introduce a completely new technology for monitoring the viscoelastic properties of clots during formation and breakdown that is well suited for use across the continuum of care from inside the hospital to ambulatory care clinics, physician offices, ambulances, and battlefields.

The CORA system, designed to produce timely and equivalent results regardless of the device location or operator, can substantially enhance the standard of care for patients with a tendency to clot, and can improve clinical outcomes at a reduced cost. The CORA system is the successor to the widely accepted Thrombelastograph® TEG®5000 hemostasis system, which is used to measure all phases and states of patient hemostasis, including a prothrombotic state. However, the existing device requires skilled operators in a hospital setting. The CORA system, which is expected to enable coagulation monitoring outside the hospital, in sites such as physician offices, will allow accessible screening for risk of heart attacks and stroke, and monitoring of anticoagulation and anti-platelet therapy.

Monitoring blood coagulation at a patient’s point of care is intended to result in better patient outcomes and fewer complications. 
 
About Coramed Technologies
Coramed Technologies was launched in 2008 by the founders of Haemoscope Corporation, creators of the currently marketed TEG® 5000 hemostasis analyzer. While the TEG 5000 is a successful, industry-leading instrument, it can only be used in a laboratory or hospital setting. Coramed has developed new CORA™ technology that will lead to a smaller, easier-to-use, CLIA-waived device that can be operated virtually anywhere. The company anticipates FDA marketing clearance of initial devices incorporating CORA technology in early 2015.

Download PDF

News and Research

Monitoring coagulation at a patient’s point of care leads to better outcomes and fewer complications.